ChroMedX Works Towards Third Version of Hemopalm Prototype Analyzer
Toronto, Ontario--(Newsfile Corp. - July 31, 2017) - ChroMedX Corp. (the "Company") (CSE: CHX) (OTCQB: CHXIF) (FSE: EIY2), developer of the HemoPalm Handheld Blood Analyzer System, is pleased to provide an update on the refinement and testing of the Company's HemoPalm System prototype. The Company completed its first HemoPalm System prototype mid-May in collaboration with rapid-prototyping firm Agile Manufacturing Inc. ChroMedX has continued to refine the design and is now in the process of...
2017-07-31 4:15 PM EDT
ChroMedx Announces Closing of Private Placement
Toronto, Ontario--(Newsfile Corp. - June 19, 2017) - ChroMedX Corp. (CSE: CHX) (OTCQB: MNLIF) (FSE: EIY2) (the "Company") is pleased to announce that it has closed a non-brokered private placement (the "Offering") of 3,100,000 units ("Units") at a price of $0.20 per Unit for aggregate gross proceeds of $620,000. Each Unit is comprised of one common share of the Company (a "Common Share") and one Common Share purchase warrant (a "Warrant"). Each Warrant entitles the holder thereof to acquire...
2017-06-19 4:30 PM EDT
ChroMedX Completes HemoPalm System Prototype
Toronto, Ontario--(Newsfile Corp. - May 19, 2017) - ChroMedX Corp. (CSE: CHX) (OTCQB: MNLIF) (FSE: EIY2) (the "Company"), developer of the HemoPalm Handheld Blood Analyzer System, is pleased to announce the completion of a HemoPalm handheld analyzer and cartridge system prototype. The HemoPalm system prototype has been developed as a collaborative effort led by ChroMedX CEO & President Ash Kaushal with key contributors internationally. The prototype system demonstrates portability and...
2017-05-19 4:25 PM EDT
ChroMedX Appoints Former Special Forces Officer Captain (Retd) Greg Falck to Advisory Board
Toronto, Ontario--(Newsfile Corp. - May 16, 2017) - ChroMedX Corp. (CSE: CHX) (OTC: MNLIF) (FSE: EIY2) (the "Company"), developer of the HemoPalm Handheld Blood Analyzer System, is pleased to announce the appointment of former Canadian Armed Forces officer, Capt (Retd) Greg Falck to the Company's advisory board. While in the military Capt Falck led the development of a multitude of diverse technologies while commanding a special forces maintenance organization, liaising directly with industry...
2017-05-16 4:05 PM EDT
ChroMedX Completes Receptor Component and Commences Packaging of HemoPalm Analyzer Prototype
Toronto, Ontario--(Newsfile Corp. - May 8, 2017) - ChroMedX Corp. (the "Company") (CSE: CHX) (OTCQB: MNLIF) (FSE: EIY2), developer of the HemoPalm Handheld Blood Analyzer System, is pleased to announce the completion of the cartridge receptor component for the HemoPalm analyzer prototype. The Company also announces the engagement of rapid prototyping firm Agile Manufacturing to complete the final assembly and packaging of the HemoPalm Analyzer prototype. The receptor is a crucial part of the...
2017-05-08 4:10 PM EDT
ChroMedX Files Enhanced Patent on Cartridge Improvements; Extends Protection to 2037
Toronto, Ontario--(Newsfile Corp. - April 24, 2017) - ChroMedX Corp. (CSE: CHX) (OTCQB: MNLIF) (FSE: EIY2) (the "Company"), developer of the HemoPalm Handheld Blood Analyzer System, is pleased to announce the filing of a second PCT (International) patent application describing its HemoPalm platform. The application's purpose is to protect innovations and improvements discovered during development and extend patent protection until 2037. ChroMedX filed a first PCT patent application entitled,...
2017-04-24 4:20 PM EDT
ChroMedX Finalizes HemoPalm Analyzer 2.0 Design
Toronto, Ontario--(Newsfile Corp. - April 18, 2017) - ChroMedX Corp. (CSE: CHX) (OTC: MNLIF) (FSE: EIY2) (the "Company"), developer of the HemoPalm Handheld Blood Analyzer System, is pleased to announce the finalization of the new HemoPalm 2.0 design. The new design reflects the evolution of diagnostics moving from laboratory based analysis to point-of-care testing (POCT). The design includes a number of new and updated features for improving diagnostic time and treatment for patients in the...
2017-04-18 4:15 PM EDT
ChroMedX Strengthens Advisory Board with New Appointments
Toronto, Ontario--(Newsfile Corp. - April 12, 2017) - ChroMedX Corp. (CSE: CHX) (OTC: MNLIF) (FSE: EIY2) (the "Company"), developer of the HemoPalm Handheld Blood Analyzer System, is pleased to announce the appointment of Dr. Brian William Cameron and John P. Ormston to the Company's advisory board. "We are very pleased to strengthen our advisory board with the appointment of John Ormston and Dr. Cameron. Dr. Cameron's practical experience and John's legal expertise adds diversity to our...
2017-04-12 4:15 PM EDT
ChroMedX Finalizes Cartridge for HemoPalm Prototype
Toronto, Ontario--(Newsfile Corp. - April 10, 2017) - ChroMedX Corp. (CSE: CHX) (OTCQB: MNLIF) (FSE: EIY2) (the "Company"), developer of the HemoPalm Handheld Blood Analyzer System, is pleased to announce the completion of the HemoPalm cartridge design for integration and use with the upcoming HemoPalm analyzer prototype. The HemoPalm Cartridge is the most integral part of the technology and is protected globally by issued and pending international patents. The development of the cartridge...
2017-04-10 3:05 AM EDT
ChroMedX Receives US Patent on Automated Ultra-Filtration System
Toronto, Ontario--(Newsfile Corp. - April 6, 2017) - ChroMedX Corp. (CSE: CHX) (OTCQB: MNLIF) (FSE: EIY2) (the "Company"), developer of the HemoPalm Handheld Blood Analyzer System, is pleased to announce that it has received formal Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its Automated Ultra Filtration (AUF) technology patent Pat. Application No. 14/725,690, which was filed on May 29, 2015. The Company's AUF technology will allow the preparation of...
2017-04-06 4:30 PM EDT
ChroMedX Announces Closing of Private Placement
Toronto, Ontario--(Newsfile Corp. - February 2, 2017) - ChroMedX Corp. (CSE: CHX) (OTCQB: MNLIF) (FSE: EIY2) (the "Company") is pleased to announce that it has closed the second and final tranche of its previously announced non-brokered private placement (the "Offering") by issuing 4,073,667 units ("Units") at a price of $0.15 per Unit for aggregate gross proceeds of $611,050.05. Each Unit is comprised of one common share of the Company (a "Common Share") and one Common Share purchase warrant...
2017-02-02 4:15 PM EST
ChroMedX Provides 2016 Development Summary and Reports on Recent Warrant Exercise and Expiration
Toronto, Ontario--(Newsfile Corp. - January 16, 2017) - ChroMedX Corp. (CSE: CHX) (OTC: MNLIF) (FSE: EIY2) (the "Company"), developer of the HemoPalm Handheld Blood Analyzer System, is pleased to provide a 2016 development summary and report on development initiatives in 2017. The Company also reports on recent expiration and exercise of warrants. In 2016 the Company's core focus was the development and testing of the HemoPalm biosensor component and to commence assembly of the HemoPalm...
2017-01-16 4:15 PM EST
ChroMedX Announces Closing of Private Placement
Toronto, Ontario--(Newsfile Corp. - December 29, 2016) - ChroMedX Corp. (CSE: CHX) (OTCQB: MNLIF) (FSE: EIY2) (the "Company") is pleased to announce that it has closed a non-brokered private placement (the "Offering") of 1,227,000 units ("Units") at a price of $0.15 per Unit for aggregate gross proceeds of $184,050. Each Unit is comprised of one common share of the Company (a "Common Share") and one Common Share purchase warrant (a "Warrant"). Each Warrant entitles the holder thereof to...
2016-12-29 5:56 PM EST
ChroMedX Collaboration with Biointerface Institute Receives OCE Grant for HemoPalm Biosensor Development
Toronto, Ontario--(Newsfile Corp. - December 2, 2016) - ChroMedX Corp. (CSE: CHX) (OTCQB: MNLIF) (FSE: EIY2) (the "Company"), developer of the HemoPalm Handheld Blood Analyzer System, is pleased to announce that it's collaboration with Dr. Leyla Soleymani and the Biointerface Institute of McMaster University has received a Voucher for Innovation and Productivity I (VIP I) grant from Ontario Centres of Excellence (OCE) for continued HemoPalm biosensor development. The VIP I program helps...
2016-12-02 8:12 PM EST
ChroMedX Receives Computer Interface and CO-oximetry Modules for Prototype Assembly
Toronto, Ontario--(Newsfile Corp. - November 29, 2016) - ChroMedX Corp. (CSE: CHX) (OTCQB: MNLIF) (FSE: EIY2) (the "Company"), developer of the HemoPalm Handheld Blood Analyzer System, is pleased to announce that the Company has taken delivery of the HemoPalm computer interface and CO-oximetry modules for assembly of a handheld prototype. The modules come from the Company's development partner, analytical equipment developer Dr. Licht GmbH, of Numbrecht, Germany. ChroMedX worked closely with...
2016-11-29 4:15 PM EST
ChroMedX Corp. Commences Biosensor Testing
Toronto, Ontario--(Newsfile Corp. - November 25, 2016) - ChroMedX Corp. (CSE: CHX) (OTCQB: MNLIF) (FSE: EIY2) (the "Company"), developer of the HemoPalm Handheld Blood Analyzer System, is pleased to announce that the Company has commenced testing of its biosensor component and is receiving positive results. Testing on the biosensors commenced earlier this month at McMaster University where the Company has conducted its biosensor development initiative since early this year. Results are now...
2016-11-25 4:15 PM EST
ChroMedX Files Global Patent Protection on HemoPalm Handheld Blood Analyzer System
Toronto, Ontario--(Newsfile Corp. - November 22, 2016) - ChroMedX Corp. (CSE: CHX) (OTCQB: MNLIF) (FSE: EIY2) (the "Company"), developer of the HemoPalmTM Handheld Blood Analyzer System, is pleased to announce the filing of global patent protection on its key patent entitled "Joint Spectroscopic and Biosensor System for Point-of-Care Testing". The system includes a handheld analyzer and disposable cartridges. ChroMedX received a US patent in September of this year and has now filed for patent...
2016-11-22 4:15 PM EST
ChroMedX Corp. Appoints Ash Kaushal to Board of Directors
Toronto, Ontario--(Newsfile Corp. - November 14, 2016) - ChroMedX Corp. (CSE: CHX) (OTCQB: MNLIF) (FSE: EIY2) (the "Company"), a developer of in vitro diagnostics and Point-of-care Testing technologies is pleased to announce the appointment of Ash Kaushal to the Company's Board of Directors in addition to his role as President and CEO as announced July 2016. The Company's Board of Directors has been very pleased with Mr. Kaushal's leadership in recent months and is proud to announce his...
2016-11-14 7:30 AM EST
ChroMedX Announces Closing of Private Placement
Toronto, Ontario--(Newsfile Corp. - October 24, 2016) - ChroMedX Corp. (CSE: CHX) (OTCQB: MNLIF) (FSE: EIY2) (the "Company") is pleased to announce that it has closed a non-brokered private placement (the "Offering") of 4,400,000 units ("Units") at a price of $0.125 per Unit for aggregate gross proceeds of $550,000. Each Unit is comprised of one common share of the Company (a "Common Share") and one Common Share purchase warrant (a "Warrant"). Each Warrant entitles the holder thereof to...
2016-10-24 4:05 PM EDT
ChroMedX Receives US Patent on Flagship HemoPalm Analyzer Technology
Toronto, Ontario--(Newsfile Corp. - September 26, 2016) - ChroMedX Corp. (CSE: CHX) (OTCQB: MNLIF) (FSE: EIY2) (the "Company"), a developer of in vitro diagnostics and point-of-care testing (POCT) technologies is pleased to announce that it has received formal Notice of Allowance from the United States Patent and Trademark Office (USPTO) for Pat. Application No. 15/144,073, which is a continuation of PCT/CA2015/050455 filed 20th May 2015. The allowed patent is published under publication...
2016-09-26 4:35 PM EDT